Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients

Numerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether...

Full description

Bibliographic Details
Main Authors: Kristina Neugebauer, Christine Hammans, Tobias Wensing, Vinod Kumar, Wolfgang Grodd, Lea Mevissen, Melanie A. Sternkopf, Ana Novakovic, Ted Abel, Ute Habel, Thomas Nickl-Jockschat
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/full
id doaj-bac30f3c4b174345b2bdcb51ec70d82d
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Kristina Neugebauer
Kristina Neugebauer
Christine Hammans
Christine Hammans
Tobias Wensing
Vinod Kumar
Vinod Kumar
Vinod Kumar
Wolfgang Grodd
Lea Mevissen
Lea Mevissen
Melanie A. Sternkopf
Melanie A. Sternkopf
Ana Novakovic
Ana Novakovic
Ted Abel
Ute Habel
Ute Habel
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
spellingShingle Kristina Neugebauer
Kristina Neugebauer
Christine Hammans
Christine Hammans
Tobias Wensing
Vinod Kumar
Vinod Kumar
Vinod Kumar
Wolfgang Grodd
Lea Mevissen
Lea Mevissen
Melanie A. Sternkopf
Melanie A. Sternkopf
Ana Novakovic
Ana Novakovic
Ted Abel
Ute Habel
Ute Habel
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
Frontiers in Psychiatry
schizophrenia
nerve growth factor
voxel-based morphometry
neuroimaging
functional decoding
author_facet Kristina Neugebauer
Kristina Neugebauer
Christine Hammans
Christine Hammans
Tobias Wensing
Vinod Kumar
Vinod Kumar
Vinod Kumar
Wolfgang Grodd
Lea Mevissen
Lea Mevissen
Melanie A. Sternkopf
Melanie A. Sternkopf
Ana Novakovic
Ana Novakovic
Ted Abel
Ute Habel
Ute Habel
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
Thomas Nickl-Jockschat
author_sort Kristina Neugebauer
title Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
title_short Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
title_full Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
title_fullStr Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
title_full_unstemmed Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
title_sort nerve growth factor serum levels are associated with regional gray matter volume differences in schizophrenia patients
publisher Frontiers Media S.A.
series Frontiers in Psychiatry
issn 1664-0640
publishDate 2019-04-01
description Numerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether there was a correlation between NGF serum levels and gray matter volume (GMV) in schizophrenia patients. Further, we investigated whether there was an overlap between the correlative findings and cross-sectional GMV differences between schizophrenia patients (n = 18) and healthy controls (n = 19). Serum NGF was significantly correlated to GMV in the left prefrontal lobe, the left midcingulate cortex, and the brainstem in schizophrenia patients. However, we did not find any correlations of NGF serum levels with GMV in healthy controls. Schizophrenia patients showed smaller GMV than healthy controls in brain regions located in the bilateral limbic system, bilateral parietal lobe, bilateral insula, bilateral primary auditory cortex, left frontal lobe, and bilateral occipital regions. In a conjunction analysis, GMV in the left midcingulate cortex (MCC) appears negatively correlated to NGF serum levels in the group of schizophrenia patients and also to be reduced compared to healthy controls. These results suggest an increased vulnerability of schizophrenia patients to changes in NGF levels compared to healthy controls and support a role for NGF signaling in the pathophysiology of schizophrenia. As our pilot study is exploratory in nature, further studies enrolling larger sample sizes will be needed to further corroborate our findings and to investigate the influence of additional covariates.
topic schizophrenia
nerve growth factor
voxel-based morphometry
neuroimaging
functional decoding
url https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/full
work_keys_str_mv AT kristinaneugebauer nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT kristinaneugebauer nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT christinehammans nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT christinehammans nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT tobiaswensing nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT wolfganggrodd nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT leamevissen nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT leamevissen nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT melanieasternkopf nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT melanieasternkopf nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT ananovakovic nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT ananovakovic nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT tedabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT utehabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT utehabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients
_version_ 1724884534963470336
spelling doaj-bac30f3c4b174345b2bdcb51ec70d82d2020-11-25T02:17:53ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-04-011010.3389/fpsyt.2019.00275418237Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia PatientsKristina Neugebauer0Kristina Neugebauer1Christine Hammans2Christine Hammans3Tobias Wensing4Vinod Kumar5Vinod Kumar6Vinod Kumar7Wolfgang Grodd8Lea Mevissen9Lea Mevissen10Melanie A. Sternkopf11Melanie A. Sternkopf12Ana Novakovic13Ana Novakovic14Ted Abel15Ute Habel16Ute Habel17Thomas Nickl-Jockschat18Thomas Nickl-Jockschat19Thomas Nickl-Jockschat20Thomas Nickl-Jockschat21Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyMax-Planck-Institute for Biological Cybernetics, Tübingen, GermanyMax-Planck-Institute for Biological Cybernetics, Tübingen, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyIowa Neuroscience Institute, University of Iowa, Iowa City, IA, United StatesDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyIowa Neuroscience Institute, University of Iowa, Iowa City, IA, United StatesDepartment of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, United StatesNumerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether there was a correlation between NGF serum levels and gray matter volume (GMV) in schizophrenia patients. Further, we investigated whether there was an overlap between the correlative findings and cross-sectional GMV differences between schizophrenia patients (n = 18) and healthy controls (n = 19). Serum NGF was significantly correlated to GMV in the left prefrontal lobe, the left midcingulate cortex, and the brainstem in schizophrenia patients. However, we did not find any correlations of NGF serum levels with GMV in healthy controls. Schizophrenia patients showed smaller GMV than healthy controls in brain regions located in the bilateral limbic system, bilateral parietal lobe, bilateral insula, bilateral primary auditory cortex, left frontal lobe, and bilateral occipital regions. In a conjunction analysis, GMV in the left midcingulate cortex (MCC) appears negatively correlated to NGF serum levels in the group of schizophrenia patients and also to be reduced compared to healthy controls. These results suggest an increased vulnerability of schizophrenia patients to changes in NGF levels compared to healthy controls and support a role for NGF signaling in the pathophysiology of schizophrenia. As our pilot study is exploratory in nature, further studies enrolling larger sample sizes will be needed to further corroborate our findings and to investigate the influence of additional covariates.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/fullschizophrenianerve growth factorvoxel-based morphometryneuroimagingfunctional decoding